Friday, March 12, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM) and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Netflix shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (+52.7% vs. +83%). The Zacks analyst believes that Netflix has been benefiting from heavy investments in the production and distribution of localized, foreign-language content.

Higher numbers of originals are expected to aid user-base growth in 2021 despite rising competition from Apple TV+, Amazon prime video, HBO Max, Disney+, Peacock, Discovery+ and TikTok. The company plans to release at least one new original film every week in 2021. User-friendly features like Downloads For You and more efficient Parental Controls are key positives.

The launch of low-priced mobile plans is also expected to expand Netflix’s subscriber base in Asia Pacific. However, Netflix’s leveraged balance sheet and higher streaming obligation is also a concern.

(You can read the full research report on Netflix here >>>)

Shares of Toyota have gained +12.2% in the last six months against the Zacks Foreign Automotive industry’s gain of +29.9%. The Zacks analyst believes that the firm’s sharp focus on electric vehicles (EVs) and driverless cars offer ample growth visibility.

Toyota targets to achieve 40% of its global sales from EVs by 2025 and nearly 70% by 2035. Partnership with Subaru and Mazda is likely to drive Toyota's electrification plans. Collaboration with Hino, Aurora, Uber and Pony.ai also augur well. Thus, Toyota is viewed as a lucrative bet.

Toyota put up a stellar show in fiscal third quarter 2021, with earnings and sales not just beating estimates but also rising year over year. The upward revision of its fiscal 2021 view is encouraging. The company now projects 2021 operating income at ¥2,000 billion, up from the prior estimate of ¥1,300 billion.

(You can read the full research report on Toyota Motor here >>>)

AbbVie’s shares have gained +3.2% over the past three months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +1.6%. The Zacks analyst believes that AbbVie’s key drug, Humira, continues to see strong demand trends in the United States.

AbbVie has been successful in expanding labels of its cancer drugs, Imbruvica and Venclexta. It has an impressive late-stage pipeline with several early/mid-stage pipeline candidates that have blockbuster potential. Its two new immunology drugs, Skyrizi and Rinvoq, performed beyond expectations in 2020.

Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic areas. However, sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Also, the decline in HCV drug Mavyret’s sales is a concern.

(You can read the full research report on AbbVie here >>>)

Other noteworthy reports we are featuring today include Merck (MRK), Advanced Micro Devices (AMD) and Sinopec (SNP).

5G Revolution: 3 Stocks to Make Your Move

With super high data speed, it will make current cell phones obsolete and unlock the full potential of big data, cloud computing, and artificial intelligence. In the next few years this industry is predicted to create 22 million jobs and a stunning $12.3 trillion in revenue.

Today you have an historic chance to pursue almost unimaginable gains like Microsoft, Netflix, and Apple in their early phases. Zacks has released a Special Report that reveals our . . .

• Smartest stock for 5G telecom
• Safest investment in 5G hardware
• Single best 5G buy of all!

Download now. Today the report is FREE >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>